News
ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with ...
Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback